Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Yosuke Kitagawa,Ami Kobayashi,Daniel P Cahill,Hiroaki Wakimoto,Shota Tanaka
DOI: https://doi.org/10.1016/j.bbcan.2024.189102
Abstract:Gliomas with Isocitrate dehydrogenase (IDH) mutation represent a discrete category of primary brain tumors with distinct and unique characteristics, behaviors, and clinical disease outcomes. IDH mutations lead to aberrant high-level production of the oncometabolite D-2-hydroxyglutarate (D-2HG), which act as a competitive inhibitor of enzymes regulating epigenetics, signaling pathways, metabolism, and various other processes. This review summarizes the significance of IDH mutations, resulting upregulation of D-2HG and the associated molecular pathways in gliomagenesis. With the recent finding of clinically effective IDH inhibitors in these gliomas, this article offers a comprehensive overview of the new era of innovative therapeutic approaches based on mechanistic rationales, encompassing both completed and ongoing clinical trials targeting gliomas with IDH mutations.
What problem does this paper attempt to address?